S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
S&P 500   4,513.04 (-1.18%)
DOW   34,022.04 (-1.34%)
QQQ   387.12 (-1.70%)
AAPL   164.77 (-0.32%)
MSFT   330.08 (-0.15%)
FB   310.60 (-4.27%)
GOOGL   2,821.03 (-0.60%)
AMZN   3,443.72 (-1.81%)
TSLA   1,095.00 (-4.35%)
NVDA   314.35 (-3.80%)
BABA   122.49 (-3.95%)
NIO   38.31 (-2.10%)
CGC   9.94 (-7.19%)
AMD   149.11 (-5.85%)
GE   93.00 (-2.09%)
MU   85.15 (+1.37%)
T   22.23 (-2.63%)
F   19.58 (+2.03%)
DIS   142.15 (-1.90%)
PFE   54.68 (+1.77%)
AMC   28.57 (-15.82%)
ACB   6.01 (-6.39%)
BA   188.19 (-4.88%)
NYSE:SNN

Smith & Nephew Stock Forecast, Price & News

$32.21
+0.06 (+0.19%)
(As of 12/1/2021 12:00 AM ET)
Add
Compare
Today's Range
$32.21
$33.07
50-Day Range
$32.15
$37.15
52-Week Range
$32.03
$46.10
Volume
770,458 shs
Average Volume
519,115 shs
Market Capitalization
$14.16 billion
P/E Ratio
N/A
Dividend Yield
1.74%
Beta
0.7
30 days | 90 days | 365 days | Advanced Chart
Receive SNN News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.


Smith & Nephew logo

About Smith & Nephew

Smith & Nephew PLC engages in the development, manufacture, marketing, and sale of medical devices. It operates through the following segments: Orthopaedics; Sports Medicine and ENT; and Advanced Wound Management. The Orthopaedics and Sports Medicine and ENT segment consists of the following businesses: knee implants, hip implants, other reconstruction, trauma, sports medicine joint repair, arthroscopic enabling technologies and ENT. The Advanced Wound Management segment comprises advanced wound care, advanced wound bioactives and advanced wound devices businesses. The company was founded by Thomas James Smith in 1856 and is headquartered in London, the United Kingdom.

Headlines

Smith & Nephew (NYSE:SNN) Reaches New 52-Week Low at $32.57
November 30, 2021 |  americanbankingnews.com
Smith & Nephew (NYSE:SNN) Sets New 1-Year Low at $33.48
November 23, 2021 |  americanbankingnews.com
Smith & Nephew PLC (SNN) Q3 2021 Earnings Call Transcript
November 4, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
18,000
Year Founded
1856

Sales & Book Value

Annual Sales
$4.56 billion
Cash Flow
$2.37 per share
Book Value
$12.04 per share

Profitability

Pretax Margin
N/A

Debt

Price-To-Earnings

Miscellaneous

Free Float
435,249,000
Market Cap
$14.16 billion
Optionable
Optionable

Company Calendar

Last Earnings
11/17/2014
Ex-Dividend
9/30/2021
Dividend Payable
10/27/2021
Today
12/01/2021
Fiscal Year End
12/31/2021

Social Links


MarketRank

Overall MarketRank

1.98 out of 5 stars

Medical Sector

648th out of 1,392 stocks

Surgical Appliances & Supplies Industry

14th out of 27 stocks

Analyst Opinion: 3.4Community Rank: 3.6Dividend Strength: 1.7Insider Behavior: 0.0Valuation: 1.3 5 -4 -3 -2 -1 -












Smith & Nephew (NYSE:SNN) Frequently Asked Questions

Is Smith & Nephew a buy right now?

8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last twelve months. There are currently 2 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Smith & Nephew stock.
View analyst ratings for Smith & Nephew
or view top-rated stocks.

How has Smith & Nephew's stock been impacted by Coronavirus (COVID-19)?

Smith & Nephew's stock was trading at $38.73 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, SNN shares have decreased by 16.8% and is now trading at $32.21.
View which stocks have been most impacted by COVID-19
.

Are investors shorting Smith & Nephew?

Smith & Nephew saw a drop in short interest during the month of October. As of October 29th, there was short interest totaling 677,300 shares, a drop of 23.7% from the October 14th total of 887,100 shares. Based on an average trading volume of 423,400 shares, the days-to-cover ratio is currently 1.6 days. Currently, 0.2% of the company's shares are short sold.
View Smith & Nephew's Short Interest
.

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) issued its quarterly earnings data on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share for the quarter, topping analysts' consensus estimates of $0.39 by $0.59.
View Smith & Nephew's earnings history
.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew announced a semi-annual dividend on Friday, August 13th. Investors of record on Friday, October 1st will be paid a dividend of $0.288 per share on Wednesday, October 27th. This represents a dividend yield of 1.9%. The ex-dividend date is Thursday, September 30th.
View Smith & Nephew's dividend history
.

Is Smith & Nephew a good dividend stock?

Smith & Nephew pays an annual dividend of $0.56 per share and currently has a dividend yield of 1.74%.
View Smith & Nephew's dividend history.

What price target have analysts set for SNN?

8 brokerages have issued 12-month price objectives for Smith & Nephew's stock. Their forecasts range from $46.50 to $55.00. On average, they expect Smith & Nephew's stock price to reach $50.75 in the next year. This suggests a possible upside of 57.6% from the stock's current price.
View analysts' price targets for Smith & Nephew
or view top-rated stocks among Wall Street analysts.

Who are Smith & Nephew's key executives?

Smith & Nephew's management team includes the following people:
  • Roland D. Diggelmann, Chief Executive Officer & Non-Executive Director
  • Paul Connolly, President-Global Operations
  • Anne-Francoise Nesmes, Chief Financial Officer & Executive Director
  • Vasant Padmanabhan, President-Research & Development
  • Catheryn O'Rourke, Chief Legal & Compliance Officer

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by many different institutional and retail investors. Top institutional investors include Cambiar Investors LLC (0.39%), Royal Bank of Canada (0.25%), Raymond James & Associates (0.17%), Prio Wealth Limited Partnership (0.14%), Credit Suisse AG (0.12%) and Goldman Sachs Group Inc. (0.11%).

Which institutional investors are selling Smith & Nephew stock?

SNN stock was sold by a variety of institutional investors in the last quarter, including Credit Suisse AG, Two Sigma Investments LP, Cambiar Investors LLC, Goldman Sachs Group Inc., Neuberger Berman Group LLC, BlackRock Inc., Comerica Bank, and Citigroup Inc..

Which institutional investors are buying Smith & Nephew stock?

SNN stock was bought by a variety of institutional investors in the last quarter, including Raymond James & Associates, Dimensional Fund Advisors LP, Royal Bank of Canada, Balyasny Asset Management LLC, Balyasny Asset Management LLC, Cinctive Capital Management LP, Point72 Asset Management L.P., and Magnetar Financial LLC.

How do I buy shares of Smith & Nephew?

Shares of SNN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $32.21.

How much money does Smith & Nephew make?

Smith & Nephew has a market capitalization of $14.16 billion and generates $4.56 billion in revenue each year.

How many employees does Smith & Nephew have?

Smith & Nephew employs 18,000 workers across the globe.

When was Smith & Nephew founded?

Smith & Nephew was founded in 1856.

What is Smith & Nephew's official website?

The official website for Smith & Nephew is www.smith-nephew.com.

Where are Smith & Nephew's headquarters?

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The medical equipment provider can be reached via phone at 441923477100, via email at [email protected], or via fax at 44-20-7930-3353.


This page was last updated on 12/1/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.